Status:
COMPLETED
A Phase I Study of LY3502970 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
21-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how lo...
Eligibility Criteria
Inclusion
- Are overtly healthy as determined by medical evaluation
- Participants with body weight of 45 kilograms (kg) or more and body mass index within the range 18.5 to 35.0 kilograms per meter squared (kg/m²), inclusive
- Males who agree to use highly effective or effective methods of contraception and women not of childbearing potential may participate in this study
Exclusion
- Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
- Women who are lactating and women of child bearing potential (WOCBP) are excluded from the study
- Participants who regularly use known drugs of abuse or show positive findings on drug screen
Key Trial Info
Start Date :
October 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 5 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06085482
Start Date
October 19 2023
End Date
January 5 2024
Last Update
March 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research Inc
Madison, Wisconsin, United States, 53704